Difference between revisions of "Part:BBa K567014"
(→Construction of BBa_K567014) |
|||
(5 intermediate revisions by 3 users not shown) | |||
Line 2: | Line 2: | ||
<partinfo>BBa_K567014 short</partinfo> | <partinfo>BBa_K567014 short</partinfo> | ||
− | T7 promoter-''metG''(mutated). This biobrick is constructed by putting the mutated ''metG'' (Met-RS) under the control of T7 promoter and lac operator. We have cloned ''metG'' from E.coli and have used error-prone PCR to amplify the ''metG''. | + | T7 promoter-''metG''(mutated). This biobrick is constructed by putting the mutated ''metG'' (Met-RS) under the control of T7 promoter and lac operator. We have cloned ''metG'' from E.coli and have used error-prone PCR to amplify the ''metG''. KanR gene with start codon substituted for CGA is used to testify the function of mutated ''metG''. When this biobrick and ''metY''-CGA (BBa_K567016) are co-transformed into the cell, the cells can survive on the LB Kanamycin plate. |
===Construction of BBa_K567014=== | ===Construction of BBa_K567014=== | ||
− | In order to charge Met to tRNA<sup>Met</sup> with mutated anticodon, we need to deprive MetRS of its anticodon specificity. Directed Evolution Strategy is used. Error-prone PCR is used to introduce random mutations into MetRS.When this part, ''metY''-CGA (BBa_K567016) and | + | In order to charge Met to tRNA<sup>Met</sup> with mutated anticodon, we need to deprive MetRS of its anticodon specificity. Directed Evolution Strategy is used. Error-prone PCR is used to introduce random mutations into MetRS.When this part, ''metY''-CGA (BBa_K567016) and KanR (BBa_K567020) are co-transformed into the cell, the cell is expected to survive Kan. We screened the MetRS obtained through error-prone PCR using Kanamycin and obtained one target mutant. |
− | + | ||
===Characterization of BBa_K567015=== | ===Characterization of BBa_K567015=== | ||
− | When this part, ''metY''-CGA (BBa_K567016) and | + | When this part, ''metY''-CGA (BBa_K567016) and KanR (BBa_K567020) are co-transformed into the cell, the cell is expected to survive Kanamycin. This enzyme lost specificity for tRNA<sup>Met</sup> anticodon while maintained aminoacylation ability. |
− | [[image:11SJTU-initial_codon_result.jpg|frame|center| | + | [[image:11SJTU-initial_codon_result.jpg|frame|center|Fig. Growth of ER2566 with a. ''metG''N + ''metY''-CGA, b. ''metG''M + ''metY''-CGA, c. + ''metG''N, d. + ''metG''M. Growth medium (left): LB Kana+Tet. Growth medium (right): LB Kana.]] |
− | Cell growth shows that the cells show | + | Cell growth shows that the cells show Kanamycin resistance only when both modified MetRS (''metG''M) and modified tRNA<sup>Met</sup>(''metY''-CGA) are transformed into the cell, proving that ''metG''M works well. |
For more information concerning this part, please see [http://2011.igem.org/Team:SJTU-BioX-Shanghai 2011 SJTU-BioX-iGEM] | For more information concerning this part, please see [http://2011.igem.org/Team:SJTU-BioX-Shanghai 2011 SJTU-BioX-iGEM] | ||
+ | |||
+ | Related Biobrick: | ||
+ | |||
+ | PT7-''metG''N ([https://parts.igem.org/wiki/index.php?title=Part:BBa_K567015 BBa_K567015]) | ||
+ | |||
+ | ''metY''-CGA ([https://parts.igem.org/wiki/index.php?title=Part:BBa_K567016 BBa_K567016]) | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Latest revision as of 03:36, 29 October 2011
PT7-metGM
T7 promoter-metG(mutated). This biobrick is constructed by putting the mutated metG (Met-RS) under the control of T7 promoter and lac operator. We have cloned metG from E.coli and have used error-prone PCR to amplify the metG. KanR gene with start codon substituted for CGA is used to testify the function of mutated metG. When this biobrick and metY-CGA (BBa_K567016) are co-transformed into the cell, the cells can survive on the LB Kanamycin plate.
Construction of BBa_K567014
In order to charge Met to tRNAMet with mutated anticodon, we need to deprive MetRS of its anticodon specificity. Directed Evolution Strategy is used. Error-prone PCR is used to introduce random mutations into MetRS.When this part, metY-CGA (BBa_K567016) and KanR (BBa_K567020) are co-transformed into the cell, the cell is expected to survive Kan. We screened the MetRS obtained through error-prone PCR using Kanamycin and obtained one target mutant.
Characterization of BBa_K567015
When this part, metY-CGA (BBa_K567016) and KanR (BBa_K567020) are co-transformed into the cell, the cell is expected to survive Kanamycin. This enzyme lost specificity for tRNAMet anticodon while maintained aminoacylation ability.
Cell growth shows that the cells show Kanamycin resistance only when both modified MetRS (metGM) and modified tRNAMet(metY-CGA) are transformed into the cell, proving that metGM works well.
For more information concerning this part, please see [http://2011.igem.org/Team:SJTU-BioX-Shanghai 2011 SJTU-BioX-iGEM]
Related Biobrick:
PT7-metGN (BBa_K567015)
metY-CGA (BBa_K567016)
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal EcoRI site found at 2257
Illegal XbaI site found at 48
Illegal PstI site found at 1508 - 12INCOMPATIBLE WITH RFC[12]Illegal EcoRI site found at 2257
Illegal PstI site found at 1508 - 21INCOMPATIBLE WITH RFC[21]Illegal EcoRI site found at 2257
Illegal BamHI site found at 1951 - 23INCOMPATIBLE WITH RFC[23]Illegal EcoRI site found at 2257
Illegal XbaI site found at 48
Illegal PstI site found at 1508 - 25INCOMPATIBLE WITH RFC[25]Illegal EcoRI site found at 2257
Illegal XbaI site found at 48
Illegal PstI site found at 1508 - 1000COMPATIBLE WITH RFC[1000]